AMATEUR ICE HOCKEY PLAYER BANNED AND FINED FOR DOPING CASE
Swiss Sport Integrity (SSI) has imposed, on 17 June 2026, a three-year suspension upon an amateur ice hockey player for possession and attempted trafficking of prohibited substances and has fined him.
During a postal inspection, a package containing the prohibited substances tamoxifen, oxandrolone, stanozolol, and clenbuterol, addressed to an amateur athlete, was seized by the Federal Office of Customs and Border Security (FOCB) and forwarded to SSI.
In accordance with the Federal Act on the Promotion of Sport (FAPS), SSI subsequently ordered the destruction of these products, subject to the associated costs.
As part of the disciplinary proceedings, the player was informed that the possession and use of the prohibited substances constituted a potential violation of the Swiss Olympic Anti-Doping Statute (the Anti-Doping Statute).
During the subsequent results management procedure, the player admitted to having ordered the prohibited doping substances, but for someone else.
This constitutes a violation of Article 2.6 (possession) and Article 2.7 (attempted trafficking) of the Anti-Doping Statute.
The player subsequently decided to accept an agreement proposed by SSI under Article 10.8.1 of the Anti-Doping Statute, which provides for a three-year suspension (instead of four years) and a fine of 150 Swiss francs as a sanction related to results management.
The suspension is effective from 20 May 2026 and applies to all sports and all positions within sport, on a worldwide basis.
SSI reminds all athletes that the legal foundations of clean sport rest on the Anti-Doping Statute and on national laws. The Act Respecting the Promotion of Sport penalises anyone who, for doping purposes, manufactures, acquires, imports, exports, transports, procures, distributes, prescribes, markets, supplies, or possesses doping products, as well as the application of prohibited methods to third parties.
We provide legal advice and representation in doping cases, and further information is available from either Dr Lucien Valloni or Kim Gamboni by emailing them at valloni@valloni.ch and gamboni@valloni.ch respectively.